Collateral sensitivity of antibiotic-resistant microbes

Trends in Microbiology

Volumn 23, Issue 7, 2015, Pages 401-407

  Pál, Csaba ^a   Papp, Balázs ^a   Lázár, Viktória ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Antibiotic resistance; Collateral sensitivity; Cross resistance; Experimental evolution; Multidrug resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CEFOXITIN; CHLORAMPHENICOL; CHLOROQUINE; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOXYCYCLINE; ERYTHROMYCIN; IDI 3783; KANAMYCIN; NALIDIXIC ACID; NITROFURANTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TOBRAMYCIN; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; BACTERIAL SURVIVAL; CANDIDA ALBICANS; COLLATERAL SENSITIVITY; CROSS RESISTANCE; DNA SUPERCOILING; ESCHERICHIA COLI; GENE; GENE MUTATION; GENE SEQUENCE; GYRA GENE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; MALARIA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLEIOTROPY; PRIORITY JOURNAL; PROTON MOTIVE FORCE; REVIEW; TUBERCULOSIS; BACTERIAL GENOME; BACTERIUM; DIRECTED MOLECULAR EVOLUTION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; MUTATION;

ANTI-BACTERIAL AGENTS; BACTERIA; DIRECTED MOLECULAR EVOLUTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVOLUTION, MOLECULAR; GENOME, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 84937628033     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2015.02.009     Document Type: Review

References (38)

1. Bennett A.F., Lenski R.E. An experimental test of evolutionary trade-offs during temperature adaptation. Proc. Natl. Acad. Sci. U.S.A. 2007, 104(Suppl. 1):8649-8654.
2. Velicer G.J., et al. Application of traditional and phylogenetically based comparative methods to test for a trade-off in bacterial growth rate at low versus high substrate concentration. Microb. Ecol. 1999, 38:191-200.
3. Szybalski W., Bryson V. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J. Bacteriol. 1952, 64:489-499.
4. Gagneux S., et al. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946.
5. Pluchino K.M., et al. Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 2012, 15:98-105.
6. Lazar V., et al. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 2013, 9:700.
7. Imamovic L., Sommer M.O. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 2013, 5:204ra132.
8. Oz T., et al. Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution. Mol. Biol. Evol. 2014, 31:2387-2401.
9. Hancock R.E. Collateral damage. Nat. Biotechnol. 2014, 32:66-68.
10. Lazar V., et al. Genome-wide analysis captures the determinants of the antibiotic cross-resistance interaction network. Nat. Commun. 2014, 5:4352.
11. Mayers D.L., et al. Antimicrobial Drug Resistance 2009, Humana Press, New York.
12. Palmer A.C., Kishony R. Opposing effects of target overexpression reveal drug mechanisms. Nat. Commun. 2014, 5:4296.
13. Toprak E., et al. Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 2012, 44:101-105.
14. Poole K. Bacterial stress responses as determinants of antimicrobial resistance. J. Antimicrob. Chemother. 2012, 67:2069-2089.
15. Dragosits M., et al. Evolutionary potential, cross-stress behavior and the genetic basis of acquired stress resistance in Escherichia coli. Mol. Syst. Biol. 2013, 9:643.
16. Oshima T., et al. Transcriptome analysis of all two-component regulatory system mutants of Escherichia coli K-12. Mol. Microbiol. 2002, 46:281-291.
17. Venkatesh B., et al. The Erwinia chrysanthemi 3937 PhoQ sensor kinase regulates several virulence determinants. J. Bacteriol. 2006, 188:3088-3098.
18. Webber M.A., et al. Clinically relevant mutant DNA gyrase alters supercoiling, changes the transcriptome, and confers multidrug resistance. MBio 2013, 4:e00273-e313.
19. Damper P.D., Epstein W. Role of the membrane potential in bacterial resistance to aminoglycoside antibiotics. Antimicrob. Agents Chemother. 1981, 20:803-808.
20. Baumert N., et al. Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants. Microb. Drug Resist. 2002, 8:253-260.
21. Merlin T.L., et al. Aminoglycoside uptake increased by tet gene expression. Antimicrob. Agents Chemother. 1989, 33:1549-1552.
22. Heisig P., Tschorny R. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob. Agents Chemother. 1994, 38:1284-1291.
23. Conrad S., et al. gyrA mutations in high-level fluoroquinolone-resistant clinical isolates of Escherichia coli. J. Antimicrob. Chemother. 1996, 38:443-455.
24. Besier S., et al. Molecular analysis of fusidic acid resistance in Staphylococcus aureus. Mol. Microbiol. 2003, 47:463-469.
25. Macvanin M., et al. Fusidic acid-resistant EF-G perturbs the accumulation of ppGpp. Mol. Microbiol. 2000, 37:98-107.
26. Nagaev I., et al. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 2001, 40:433-439.
27. Macvanin M., Hughes D. Hyper-susceptibility of a fusidic acid-resistant mutant of Salmonella to different classes of antibiotics. FEMS Microbiol. Lett. 2005, 247:215-220.
28. Hastings M.D., Sibley C.H. Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13137-13141.
29. Vincent B.M., et al. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol. 2013, 11:e1001692.
30. Gogtay N., et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst. Rev. 2013, 10:CD008492.
31. Mitchison D.A. Prevention of drug resistance by combined drug treatment of tuberculosis. Handb. Exp. Pharmacol. 2012, 211:87-98.
32. Thompson M.A., et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012, 308:387-402.
33. Lehar J., et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 2009, 27:659-666.
34. Lukens A.K., et al. Harnessing evolutionary fitness in Plasmodium falciparum for drug discovery and suppressing resistance. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:799-804.
35. Munck C., et al. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci. Transl. Med. 2014, 6:262ra156.
36. Kim S., et al. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:14494-14499.
37. Suzuki S., et al. Prediction of antibiotic resistance by gene expression profiles. Nat. Commun. 2014, 5:5792.
38. Cui L., et al. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 2010, 54:5222-5233.